ERBB2 and gastric cancer: It was reported there was a synergistic effect of HER2-targeted therapy and immunotherapy [51], which might explain the recent accelerated approval of pembrolizumab in combination with trastuzumab plus chemotherapy for patients with HER2+ gastric cancer by FDA [52].